Point-of-care diagnosticsTechnology #2017-342
Questions about this technology? Ask a Technology Manager
The nucleic acid market is expected to grow beyond US$4,900 million by end of 2027 with a compound annual growth of 7.5% from 2017-2027. Current detection of pathogen nucleic acids is performed in the centralized clinical laboratories. This is costly, time-consuming and requires trained personnel. Therefore, there is a need for easy-to-use point-of-care diagnostics.
This is a novel molecular platform that enables point-of-care visual and modular detection of nucleic acids. It has been clinically validated and shown to perform well against a clinical gold standard test (Cobas® HPV) with a high detection accuracy of area under the curve = 0.965 for HPV16 and area under the curve = 0.944 for HPV18. Furthermore, by expanding the intra-subtype coverage, it was able to detect infections in samples that were missed by the commercial test.
Stage of Development
Initially targeting the markets for diagnosis and screening of infectious diseases. Additional markets can be pursued wherever detection of specific nucleic acids is required:
· Genetic diseases
· Water and air quality monitoring
· Food and agriculture testing
· Fast (<2 hours)
· Sensitive (<10 amol)
· Can be readily read out with the naked eye and quantified with smartphones.
· With versatile microfluidic design to complement the modular assay, a diverse array of pathogens on demand can be tested with a plug-in system.